What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
No news is good news - banner Kisqali

Reimbursement


Early Breast Cancer (eBC) 

KISQALI® is reimbursed in Belgium starting July 1st 2025 for use in patients with HR+/HER2- early breast cancer1

For those with HR+/HER2- eBC, this means a 28.5% reduced risk of recurrence at 4 years with KISQALI + NSAI vs NSAI alone.*2

KISQALI is eligible in a broad range of patients with HR+/HER2- eBC, and also offers a manageable safety profile † and maintained QoL.‡1,3 KISQALI can be added as adjuvant treatment up to 12 months following ET initiation.1
 

Metastatic/Advanced Breast Cancer (mBC / aBC)

Kisqali® is reimbursed in Belgium for use in patients with HR+/HER2- locally advanced or metastatic breast cancer1
 

Check the reimbursement conditions: 

INAMI / RIZIV website

Request reimbursement:
 

E-Health
space

Steps to follow:

  1. Choose the language
  2. Click on healthcare professional
  3. In the “service online” tab, click firstly on “chapter IV”, secondly on “access to chapter IV” 
  4. Register yourself with “continue with electronic identity card”
  5. Browse and complete the different procedures
  6. Check your pharmacist has received the reimbursement authorization 
Expert Perspectives on Kisqali Reimbursement in eBC VIDEO

* Data from the NATALEE trial (N=5101). Primary endpoint was iDFS. At 3 years, risk of invasive disease was reduced by 25.1% for KISQALI + NSAI vs NSAI alone. HR 0.749; 95% CI: 0.628–0.892. ARR=3.1%.5 At 4 years, risk of invasive disease was reduced by 28.51% for KISQALI + NSAI vs NSAI alone. HR 0.715; 95% CI: 0.609–0.840. ARR=4,9%6.

† The majority of adverse events were transient, manageable, and reversible with dose reduction or interruption.1 
‡ The EORTC QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status/QoL scale, and a number of single items.4
 
aBC, advanced breast cancer; AI, aromatase inhibitor; ARR, absolute risk reduction; CI, confidence interval; eBC, early breast cancer; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer, core quality of life questionnaire; EU, European Union; HER2-, human epidermal growth factor receptor 2 negative; HR, hazard ratio; HR+, hormone receptor positive; LHRH, luteinising hormone releasing hormone; NSAI, nonsteroidal aromatase inhibitor.

 

References

  1. KISQALI (ribociclib). Summary of Product Characteristics.
  2. Fasching PA, et al. Oral LBA13. Presented at the European Society for Medical Oncology Congress 2024, 13–17 September, Barcelona, Spain.
  3. Fasching PA, et al. Abstract VP3-2023. Presented at the European Society for Medical Oncology Virtual Plenary, 14–15 September 2023.
  4. Aaronson NK, et al. J Natl Cancer Inst. 1993;85(5):365–376.
  5. Hortobagyi, SABCS 2023
  6. Fashing, ESMO 2024